Pfizer Inc.

The administration of President Donald Trump may be willing to drop proposals related to standardized biologic drug patent lengths in order to secure passage of the U.S.-Mexico-Canada Agreement, USMCA, through the U.S. House of Representatives. Setting patent protections to 10 years across the... Read more →